Canopy Growth vs Organigram Global
CGC and OGI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGC and OGI compare
Organigram Global grew revenue faster over the last twelve months (77.8% versus 10.7% for Canopy Growth).
Organigram Global scores higher on the StockData Score (4 against 3 for Canopy Growth), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGC | OGI |
|---|---|---|
| Size and price | ||
| Share price | $0.561 | $0.829 |
| Change, 1 year | −52.8% | −48.5% |
| Change, 5 years | −99.5% | −89.6% |
| Beta (5Y) | 1.89 | 1.51 |
| Employees | 1,128 | – |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 10.7% | 77.8% (better) |
| Revenue growth, 5Y average | −12.2% | 83.6% (better) |
| Profitability | ||
| Gross margin | 24.4% | 34.8% (better) |
| Operating margin | −54.2% | −5.9% (better) |
| Net margin | −87.0% | – |
| FCF margin | −25.8% | −9.5% (better) |
| Financial health | ||
| Net debt / EBITDA | – | −31.24 |
| Interest coverage | −3.7× | – |
| Current ratio | 2.82 (better) | 2.26 |
| Piotroski F-score | 5 | – |
| Ownership | ||
| Held by institutions | 6.9% | 5.7% |
| Held by insiders | 1.0% | 31.4% |
| Insider net buying, 12 months | −$393K | – |
Go deeper
- CGC stock overview
- CGC income statement
- CGC valuation and score
- OGI stock overview
- OGI income statement
- OGI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.